Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $23.43.

TEVA has been the subject of several recent research reports. Bank of America lowered their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th.

Teva Pharmaceutical Industries Trading Down 4.4 %

NYSE TEVA opened at $14.69 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock’s 50-day simple moving average is $18.70 and its two-hundred day simple moving average is $18.35. Teva Pharmaceutical Industries has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a market capitalization of $16.65 billion, a price-to-earnings ratio of -10.13, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the business. Oarsman Capital Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $44,000. Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $50,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $60,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.